Takeda Pharmaceuticals operates at the intersection of deep scientific innovation and complex global healthcare systems, with a portfolio spanning gastroenterology, oncology, neuroscience, rare diseases, and plasma-derived therapies. CEO-elect Julie Kim joins Yassaman Salas, global co-head of the Healthcare Group within Investment Banking at Goldman Sachs, to discuss the promise of precision medicine, the role of AI and real-world data in accelerating development and access, and how she plans to sharpen Takeda’s growth story while preserving its patient-first, values-driven culture.

This episode was recorded on October 31, 2025.

The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment advice, a recommendation from any Goldman Sachs entity to take any particular action, or an offer or solicitation to purchase or sell any securities or financial products. This material may contain forward-looking statements. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any ownership or license rights between any such company and Goldman Sachs.

A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs. Disclosures applicable to research with respect to issuers, if any, mentioned herein are available through your Goldman Sachs representative or at http://www.gs.com/research/hedge.html

Goldman Sachs does not endorse any candidate or any political party.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Reimagining Biopharma: Precision Medicine, Patients, and Purpose with Takeda CEO-Elect